


FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 056291-5038		Client Ref. 		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <div style="text-align: center;">  </div>		Applicant: CAMERON et al.				
		Appln. No.: 09/889,409				
		Filing Date: February 22, 2002				
		Examiner: Weddington, K. Group Art Unit: 1614				
Date: March 11, 2004 Page 1 of 1						
U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
FOREIGN PATENT DOCUMENTS						
	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract Enclosed No Enclosed No	
ER						
FR						
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)						
GR	McClellan et al., "Candesartan Cilexetil A Review of its Use in Essential Hypertension", Drugs, 1998, pp. 847-869					
HR	Graham-Smith et al., "Oxford Handbook on Clinical Pharmacology and Pharmacotherapy", Moscow, "Meditsina" 2000, part 10 (Partial Translation)					
IR	Balabolkin, "Endocrinology", Moscow, "Universum Publishing" 1998, pp 427-430 and 420-421 (Partial Translation)					
JR	Small Medical Encyclopedia, Moscow, "Meditsina", 199 pp. 110 (Partial Translation)					
KR						
LR						
MR						
NR						
OR						
PR						
Examiner: <i>W. Weddington</i>				Date Considered: 9-7-04		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						